{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:11:29Z","timestamp":1785186689379,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770111"],"award-info":[{"award-number":["81770111"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Basic Research Program of China","award":["2014CB745201"],"award-info":[{"award-number":["2014CB745201"]}]},{"name":"Research Program of Health and Family Planning Commission of Shenzhen Municipality","award":["SZXJ2018063"],"award-info":[{"award-number":["SZXJ2018063"]}]},{"name":"Special Support Funds of Shenzhen"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.leukres.2018.10.012","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T18:10:25Z","timestamp":1540491025000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression"],"prefix":"10.1016","volume":"75","author":[{"given":"Chen","family":"Huan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Yuming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Qiaoxia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.10.012_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2018.10.012_bib0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2018.10.012_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.leukres.2018.10.012_bib0020","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.10.012_bib0025","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.10.012_bib0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","article-title":"Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes","volume":"16","author":"Stagno","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.leukres.2018.10.012_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0045","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2018.10.012_bib0050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2008.01199.x","article-title":"Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients","volume":"82","author":"Bianchini","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0055","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2018.10.012_bib0060","doi-asserted-by":"crossref","first-page":"69536","DOI":"10.18632\/oncotarget.11766","article-title":"MXD1 localizes in the nucleolus, binds UBF and impairs rRNA synthesis","volume":"7","author":"Lafita-Navarro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.10.012_bib0065","first-page":"63","article-title":"The mad side of the max network_ antagonizing the function of Myc and more","volume":"302","author":"Rottmann","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0070","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.molimm.2005.11.017","article-title":"Mad1 is a transcriptional repressor of Bcl-6","volume":"43","author":"Lee","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0075","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/mc.22676","article-title":"Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene","volume":"56","author":"Zheng","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.leukres.2018.10.012_bib0080","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejcb.2011.07.005","article-title":"MAD1 and its life as a MYC antagonist: an update","volume":"91","author":"Luscher","year":"2012","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0085","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1073\/pnas.1213764109","article-title":"miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model","volume":"109","author":"Sandhu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2018.10.012_bib0090","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1038\/cddis.2014.110","article-title":"MiR-19a\/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1","volume":"5","author":"Wu","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.leukres.2018.10.012_bib0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4161\/15384047.2014.987070","article-title":"Down regulation of miR-202 modulates Mxd1 and Sin3A repressor complexes to induce apoptosis of pancreatic cancer cells","volume":"16","author":"Farhana","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.leukres.2018.10.012_bib0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-015-0407-0","article-title":"BCR\/ABL1 and BCR are under the transcriptional control of the MYC oncogene","volume":"14","author":"Sharma","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.leukres.2018.10.012_bib0105","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","article-title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients","volume":"24","author":"Marega","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.10.012_bib0110","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/MCB.11.4.1854","article-title":"Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines","volume":"11","author":"Shah","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0115","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1093\/nar\/18.23.7119","article-title":"Unique organization of the human BCR gene promoter","volume":"18","author":"Zhu","year":"1990","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.leukres.2018.10.012_bib0120","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014357","article-title":"An overview of MYC and its interactome","volume":"4","author":"Conacci-Sorrell","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.leukres.2018.10.012_bib0125","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/MCB.21.3.691-702.2001","article-title":"The max network gone mad","volume":"21","author":"Baudino","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1101\/gad.907901","article-title":"Regulation of cyclin D2 gene expression by the Myc\/Max\/Mad network: myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter","volume":"15","author":"Bouchard","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.leukres.2018.10.012_bib0135","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.10.012_bib0140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond--exploring the full potential of targeted therapy for CML","volume":"6","author":"Quintas-Cardama","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.10.012_bib0145","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/sj.leu.2402309","article-title":"Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype","volume":"15","author":"Keeshan","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.10.012_bib0150","doi-asserted-by":"crossref","first-page":"36382","DOI":"10.18632\/oncotarget.8871","article-title":"Liposomal bortezomib is active against chronic myeloid leukemia","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.10.012_bib0155","doi-asserted-by":"crossref","first-page":"84810","DOI":"10.18632\/oncotarget.13319","article-title":"Different BCR\/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction","volume":"7","author":"Bono","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.10.012_bib0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1126\/science.1189749","article-title":"Cancer therapy reform","volume":"328","author":"Levinson","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.leukres.2018.10.012_bib0165","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618304466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618304466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T02:10:54Z","timestamp":1605319854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618304466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"alternative-id":["S0145212618304466"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.10.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}